ADXN Company Profile and Key Details

The latest quarter delivered EPS of -$1.94. The next quarter is forecast at $nan. Next year's EPS is expected at $25.10. Addex Therapeutics Ltd earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 30, 2026, missed forecasts by 36.0%. The prior quarter beat by -68.77%. Over the last six quarters, Apple has recorded several small beats. These include 190.71% in November 11, 2024.

ADXN has shown mixed momentum, losing 0.0% over the past week and -7.74% over the past quarter, though year-to-date performance is up 6.61%. Short-term trend indicators are bullishly aligned (SMA20 -8.67%, SMA50 -11.1%, SMA200 -16.01%). The stock’s 14-day RSI is 39.83 (weak momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -41.99% below its high and over 7.37% above its low. Average 10-day trading volume of 6.12 thousand shares is slightly above the 3-month average of 4.15 thousand, indicating heightened recent market interest.

Addex Therapeutics Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.13. This means the shares are trading above this model’s fair value.

Addex Therapeutics Ltd (NASDAQ:ADXN) closed at $6.06 USD, losing -$0.39 (-6.05%) from the previous close of $6.45. The stock is currently mid-range between its 52-week high and low $5.41 and $12.05. With a market capitalization of about $4.36 million, Addex Therapeutics Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~1.97). Key stats such as the average daily volume over the past year has been around 4.30 thousand shares, volume is running light vs its 52-week average. Headquartered in Geneva, None, Addex Therapeutics Ltd operates in the Healthcare sector and the Biotechnology industry. Led by CEO Timothy Mark Dyer, the company employs approximately 2 people and listed since February 12, 2020. Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders.

Addex Therapeutics Ltd has 1.27 million shares outstanding. The public float is 1.03 million shares, elevated short interest at 0.46% of float. This equals 4.98 thousand shares. The short ratio is 1.95 days. Institutional investors hold 1.13% of the float. Insiders own 0.0%.

Addex Therapeutics Ltd trades at a P/E ratio of -0.9, slightly below the S&P 500 average, with a price-to-sales ratio of 55.71 and a price-to-book ratio of 1.28 suggesting the stock is closer to book value. The P/FCF stands at -1.71, also below market averages.

Our AI price prediction model suggests that Addex Therapeutics Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.53%, with price expected at $5.90 by June 26, 2026, within a range of $5.63 to $6.16 3-Month Outlook: Projected fall of -15.81%, reaching $5.43 by September 10, 2026, with a range of $5.20 to $5.65. 1-Year Outlook: Projected gain of 75.35%, with price at $11.31 by June 11, 2027, within a range of $0.00 to $15.68.

Addex Therapeutics Ltd (NASDAQ:ADXN) shares are flat 6.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Addex Therapeutics Ltd trading at a premium to the broader market with a P/E of -0.9. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.00, suggesting 365.12% upside. Our AI forecast model points to short-term weakness (-8.53% over two weeks), a medium-term fall (-15.81% over three months), and a longer-term gain (75.35% over one year), with expected trading ranges indicating moderate volatility.